AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1594898 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 36
Study 27786012 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 and 40 mg o.d.
Number of subjects: 12
Study 27786012 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 and 100 mg o.d.
Number of subjects: 12
Study 27786012 — intervention group
Group type: COMPARATOR
Intervention: HCTZ (25 or 50 mg o.d. added if necessary)
Number of subjects: 12
Study 28380718 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults with preclinical AD
Number of subjects: 20
Study 28380718 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal older adults without preclinical AD
Number of subjects: 20
Study 29165093 — intervention group
Group type: EXPERIMENTAL
Intervention: C. tora (330 mg) three times a day
Number of subjects: 60
Study 27212646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isotretinoin
Number of subjects: 0
Study 27212646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24435788 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rehydration therapy (IVRT)
Number of subjects: 97
Study 24435788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric rehydration therapy (NGRT)
Number of subjects: 97
Study 22306046 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (n = 54)
Number of subjects: 106
Study 22306046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 52)
Number of subjects: 106
Study 20109317 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (AZENS)
Number of subjects: 132
Study 20109317 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide nasal spray (TANS)
Number of subjects: 132
Study 20109317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AZENS and TANS
Number of subjects: 132
Study 17434019 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 1.5 mg administered 3 days before ovulation (Group A)
Number of subjects: 14
Study 17434019 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 1.5 mg administered 1 day before ovulation (Group B)
Number of subjects: 14
Study 16220809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita 3D‐Master shade guide system
Number of subjects: 42
Study 16220809 — intervention group
Group type: COMPARATOR
Intervention: Vita Classical shade guide system
Number of subjects: 42
Study 12373601 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU‐containing regimens
Number of subjects: 263
Study 15321118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford position (group O)
Number of subjects: 60
Study 15321118 — intervention group
Group type: COMPARATOR
Intervention: Sitting position followed by wedged supine position (group S)
Number of subjects: 60
Study 7561554 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifater daily for the first 2 months, followed by Rifinah daily for 4 months (2 Rifater/4 Rifinah)
Number of subjects: 199
Study 7561554 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifater supplemented by ethambutol daily for the first 2 months followed by thiacetazone and isoniazid daily for 6 months (2 Rifater EMB/6 HT)
Number of subjects: 199
Study 2293363 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone infusion during surgery
Number of subjects: 28
Study 2293363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 28
Study 7373086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized amantadine (1.0 g/100 ml of distilled water)
Number of subjects: 20
Study 7373086 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 20
Study 7373086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized amantadine
Number of subjects: 20
Study 31182143 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 30 min)
Number of subjects: 50
Study 31182143 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 50
Study 28583999 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (15-minute loading intravenous infusion followed by a 24-hour maintenance dose)
Number of subjects: 1700
Study 28583999 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15-minute loading intravenous infusion followed by a 24-hour maintenance dose)
Number of subjects: 1700
Study 25583727 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of ceftazidime (loading dose of 20 mg/kg followed by 60 mg/kg/day)
Number of subjects: 34
Study 25583727 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of ceftazidime (20 mg/kg over 30 min every 8 h)
Number of subjects: 34
Study 25583727 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of ceftazidime
Number of subjects: 34
Study 25583727 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of ceftazidime
Number of subjects: 34
Study 24070232 — intervention group
Group type: EXPERIMENTAL
Intervention: Accredited exercise physiologist-coordinated resistance exercise program (12, 24, or 36 weeks)
Number of subjects: 180
Study 21841207 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vernakalant twice daily
Number of subjects: 735
Study 21841207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735
Study 21841207 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg vernakalant
Number of subjects: 735
Study 21841207 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg vernakalant
Number of subjects: 735
Study 21841207 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vernakalant
Number of subjects: 735
Study 19089780 — intervention group
Group type: EXPERIMENTAL
Intervention: cicogna system
Number of subjects: 100
Study 19089780 — intervention group
Group type: COMPARATOR
Intervention: conventional method (plastic basin)
Number of subjects: 100
Study 17159764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic-femoral block with mepivacaine 1% (15 + 25 mL)
Number of subjects: 32
Study 17159764 — intervention group
Group type: COMPARATOR
Intervention: Unilateral spinal anesthesia with 7 mg of hyperbaric bupivacaine 0.5%
Number of subjects: 32
Study 17159764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic-femoral block
Number of subjects: 32
Study 17159764 — intervention group
Group type: COMPARATOR
Intervention: Unilateral spinal anesthesia
Number of subjects: 32
Study 15709355 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degree tilt position
Number of subjects: 46
Study 15709355 — intervention group
Group type: COMPARATOR
Intervention: 90 degree lateral and supine positions
Number of subjects: 46
Study 11172834 — intervention group
Group type: COMPARATOR
Intervention: Group 0 (recombinant FSH containing no LH)
Number of subjects: 128
Study 11172834 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (urinary FSH containing <1 IU of LH)
Number of subjects: 128
Study 11172834 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 25 (hMG containing 25 IU of LH)
Number of subjects: 128
Study 11172834 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 75 (hMG containing 75 IU of LH)
Number of subjects: 128
Study 9209250 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (1.5 microgram/min)
Number of subjects: 46
Study 9209250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg/min)
Number of subjects: 46
Study 9209250 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (loading dose of 0.14 mg/kg over 20 minutes, followed by 0.63 micrograms/kg/min)
Number of subjects: 46
Study 9209250 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 46
Study 9209250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 46
Study 9209250 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 46
Study 9209250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine and Fenoterol
Number of subjects: 46
Study 8216018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic measurement of central corneal thickness
Number of subjects: 450
Study 3301861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydron‐AgSD (synthetic dressing with silver sulfadiazine 1%‐3%)
Number of subjects: 27
Study 3301861 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine 1% only (control)
Number of subjects: 27
Study 3301861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydron‐AgSD (synthetic dressing)
Number of subjects: 27
Study 29594976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-Remifentanil (DR)
Number of subjects: 198
Study 29594976 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-Remifentanil (MR)
Number of subjects: 198
Study 27126186 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib + Pemetrexed
Number of subjects: 0
Study 24664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher social interaction scores with non-family members
Number of subjects: 100
Study 24664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married
Number of subjects: 100
Study 24664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Hamilton Depression Rating Scale score
Number of subjects: 100
Study 24664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 100
Study 24664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of persons in one's family social network
Number of subjects: 100
Study 24664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher instrumental support scores
Number of subjects: 100
Study 22766835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine structure processing (FSP)
Number of subjects: 25
Study 22766835 — intervention group
Group type: COMPARATOR
Intervention: High-definition continuous interleaved sampling (HDCIS)
Number of subjects: 25
Study 19781112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive decline trajectory
Number of subjects: 201
Study 19781112 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic symptoms
Number of subjects: 201
Study 19781112 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial MMSE and age
Number of subjects: 201
Study 19781112 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE 4
Number of subjects: 201
Study 18335226 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist multidose protocol
Number of subjects: 96
Study 18335226 — intervention group
Group type: COMPARATOR
Intervention: Standard long agonist protocol
Number of subjects: 96
Study 15866679 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem treatment
Number of subjects: 10
Study 12873686 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium-89 (Arm A)
Number of subjects: 95
Study 12873686 — intervention group
Group type: COMPARATOR
Intervention: Saline (Arm B)
Number of subjects: 95
Study 10476504 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic laser cycloablation
Number of subjects: 58
Study 10476504 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 58
Study 8734342 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal ingestion in phase I with an omelette labelled with 99mTc and 150 ml water labelled with 111In
Number of subjects: 12
Study 8734342 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal ingestion in phase II with an omelette labelled with 99mTc and 150 ml water labelled with 111In
Number of subjects: 12
Study 8734342 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I
Number of subjects: 12
Study 2014891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 1.5 mg/kg
Number of subjects: 40
Study 2014891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6175947 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion
Number of subjects: 30
Study 6175947 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 6429677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (5 mg, i.v.)
Number of subjects: 10
Study 6429677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30272457 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat gesture (speech accompanied by simple rhythmic gestures)
Number of subjects: 0
Study 30272457 — intervention group
Group type: EXPERIMENTAL
Intervention: Iconic‐deictic gesture (speech accompanied by iconic and deictic gestures)
Number of subjects: 0
Study 30272457 — intervention group
Group type: COMPARATOR
Intervention: No gesture (speech only)
Number of subjects: 0
Study 26812618 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 30
Study 26812618 — intervention group
Group type: COMPARATOR
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 30
Study 24750797 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation (Lactobacillus paracasei ssp.paracasei CRL‐431, Bifidobacterium BB‐12, Streptococcus thermophilus TH‐4, fructooligosaccharide)
Number of subjects: 77
Study 24750797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 22300834 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g raw carrots
Number of subjects: 12
Study 22300834 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g cooked carrots
Number of subjects: 12
Study 22300834 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 g cooked carrots
Number of subjects: 12
Study 22300834 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylated anthocyanins
Number of subjects: 12
Study 22300834 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-acylated anthocyanins
Number of subjects: 12
Study 20486839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide with methylprednisolone
Number of subjects: 28
Study 20486839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine with methylprednisolone
Number of subjects: 28
Study 20486839 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (control)
Number of subjects: 28
Study 18336681 — intervention group
Group type: EXPERIMENTAL
Intervention: MM Nutrition Curriculum
Number of subjects: 576
Study 18336681 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 576
Study 15963088 — intervention group
Group type: EXPERIMENTAL
Intervention: DP‐b99 (1.0 mg kg(‐1))
Number of subjects: 60
Study 15963088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12459663 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (4 mg intravenous) with sham ReliefBand
Number of subjects: 90
Study 12459663 — intervention group
Group type: EXPERIMENTAL
Intervention: Acustimulation with ReliefBand (2 ml intravenous saline)
Number of subjects: 90
Study 12459663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ondansetron (4 mg intravenous) and ReliefBand
Number of subjects: 90
Study 12459663 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham treatment)
Number of subjects: 90
Study 10530769 — intervention group
Group type: EXPERIMENTAL
Intervention: 11beta-HSD 1 expression and NNK carbonyl reductase activity in human lung
Number of subjects: 0
Study 7485007 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride 25 mg t.i.d.
Number of subjects: 40
Study 7485007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7485007 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride
Number of subjects: 40
Study 1775884 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen treatment
Number of subjects: 129
Study 1775884 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive pill treatment
Number of subjects: 129
Study 1775884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 129
Study 7008592 — intervention group
Group type: EXPERIMENTAL
Intervention: J5 antiserum
Number of subjects: 136
Study 7008592 — intervention group
Group type: EXPERIMENTAL
Intervention: J5 vaccine
Number of subjects: 136
Study 30629609 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare rights advice and assistance with benefit entitlements delivered in participants’ homes by trained advisors
Number of subjects: 755
Study 30629609 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare rights advice and assistance with benefit entitlements
Number of subjects: 755
Study 30629609 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 755
Study 30290276 — intervention group
Group type: EXPERIMENTAL
Intervention: WebMAP mobile intervention
Number of subjects: 120
Study 30290276 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 27491227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangfu Congxian Decoction (CCD) 200 mL, twice daily for 2 months before IVF-ET
Number of subjects: 40
Study 27491227 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (no treatment)
Number of subjects: 40
Study 27491227 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (20 patients with tubal factors, no treatment)
Number of subjects: 40
Study 24477109 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery
Number of subjects: 35
Study 24477109 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 35
Study 24477109 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc analysis of patients with no stroke
Number of subjects: 35
Study 22992303 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (28‐day cycles at 20 mg/m(2) IV on Days 1‐2 of Cycle 1, escalating to 27 mg/m(2) IV on Days 8, 9, 15, and 16 and continuing at 27 mg/m(2) through Cycle 9 and Days 1, 2, 15, and 16 ≥ Cycle 10)
Number of subjects: 0
Study 22992303 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) regimen (corticosteroid treatment of prednisolone 30 mg, dexamethasone 6 mg, or equivalent every other day with optional cyclophosphamide 50 mg PO once daily)
Number of subjects: 0
Study 20456478 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (20‐40 mg daily)
Number of subjects: 35
Study 17381666 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg orally once daily for 5 days
Number of subjects: 10
Study 17381666 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 4 mg alone
Number of subjects: 10
Study 16285384 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous detection of cardiac, respiratory, and snoring sounds using a microphone connected to a chestpiece applied to the heart region.
Number of subjects: 30
Study 16285384 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis of event-based characteristics of sound signals.
Number of subjects: 30
Study 16285384 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic analysis for patient assessment.
Number of subjects: 30
Study 11318529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrate derivatives (predominantly fenofibrate)
Number of subjects: 0
Study 11318529 — intervention group
Group type: COMPARATOR
Intervention: HMG‐CoA reductase inhibitors (simvastatin and pravastatin)
Number of subjects: 0
Study 9596550 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 8843
Study 9596550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8843
Study 7943104 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management for 48 hours
Number of subjects: 262
Study 7943104 — intervention group
Group type: COMPARATOR
Intervention: Induction of labor 8 hours after premature rupture of membranes
Number of subjects: 262
Study 3210656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (multimodal therapy including surgical resection, polychemotherapy, and radiation therapy)
Number of subjects: 132
Study 3210656 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 132
Study 3210656 — intervention group
Group type: COMPARATOR
Intervention: Not eligible for treatment (maximal supportive care)
Number of subjects: 132
Study 31764266 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Adherence-Enhanced CBT (TI-CBTe) delivered by Rwandan youth leaders over 2 months for a total of 12 hours
Number of subjects: 356
Study 31764266 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 356
Study 28972629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 181
Study 28972629 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 181
Study 25873601 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus standard care
Number of subjects: 862
Study 25873601 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 862
Study 25873601 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (≥10 sessions)
Number of subjects: 862
Study 25873601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 862
Study 24235899 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive daytime sleepiness
Number of subjects: 435
Study 24235899 — intervention group
Group type: EXPERIMENTAL
Intervention: AHI ≥ 15
Number of subjects: 435
Study 24235899 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia subtypes
Number of subjects: 435
Study 24235899 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring loudness, snoring frequency, witnessed breathing pauses
Number of subjects: 435
Study 21410420 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg three times daily for 8 days
Number of subjects: 25
Study 21410420 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily for 8 days
Number of subjects: 25
Study 19841706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 380
Study 19841706 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided technique
Number of subjects: 380
Study 17305253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus chemotherapy
Number of subjects: 0
Study 17305253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combination therapy
Number of subjects: 0
Study 17305253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0